Intarcia presents positive results of Type 2 Diabetes study

Intarcia presents positive results of Type 2 Diabetes study

Intarcia Therapeutics, Inc. presented final results from its Phase 1b clinical study of ITCA 650 (DUROS® continuous delivery of exenatide) for the treatment of type 2 diabetes, which demonstrate substantial reductions in fasting plasma glucose (FPG) within 24 hours of the start of treatment and a sustained glucose lowering effect throughout the 28 day treatment period.  Other important results from the study were significant reductions in postprandial glucose (PPG), HbA1c and body weight.

Filed under: Business of Biotech, ,